Philips receives FDA 510(k) Clearance for TAVI Precision Treatment Planning Application

3D Model Enables Precision Treatment for Cardiac Conditions in Patients at High-Risk for Surgery

News provided by

Aug 21, 2014, 07:00 ET

ANDOVER, Mass., Aug. 21, 2014 /PRNewswire/ -- Royal Philips (NYSE: PHG AEX: PHIA) today announced it has received 510(k) clearance from the U.S. Food and Drug Administration to market its precision planning application for Transcatheter Aortic-Valve Implantation (TAVI) treatments. Through 3D imaging, the Philips TAVI application provides interventionalists with pre-procedural, high-precision positioning to treat aortic stenosis ailments.

The Philips TAVI planning application is available as part of Philips IntelliSpace Portal 6 – the company's advanced visualization and analysis solution that allows clinicians to access and analyze patient imaging and data virtually anywhere, at any time. The application features a comprehensive measurement package to accommodate virtually all types of TAVI devices.

"As our population ages, minimally invasive TAVI procedures are becoming increasingly popular in the United States, since they provide a non-surgical option for those patients who might have once been considered too high-risk for heart surgery," said Gene Saragnese, CEO, Imaging Systems, Philips Healthcare. "Treating cardiac conditions requires intense precision and our TAVI planning application delivers a solution for aortic device placement to help improve patient care."

Through advanced computed tomography imaging, the TAVI planning application provides planes and panel measurements for precisely placing TAVI devices to manage the risk of under- or oversizing of a TAVI device. It renders images into a 3D heart model to allow interventionalists to orient the device and address less-than-optimal patient cases.

The TAVI technology received FDA approval in 2011. A minimally-invasive procedure, TAVI became a major breakthrough option for high-risk patients who were deemed non-surgical candidates. This procedure can reduce mortality by 60 percent as compared to conventional surgeries¹.

The Philips TAVI application will be on display at the upcoming ESC Congress 2014 where attendees can experience Philips cardiology solutions first-hand, with a focus on the continuum of care from prevention and diagnosis, to treatment, recovery and wellness, delivering more efficient and effective cardiovascular care in the treatment of:

Coronary Artery Disease (CAD)
Structural Heart Disease (SHD)
Heart Failure (HF)

For news from the show, visit http://www.philips.com/esc and follow the #ESCcongress conversation via @PhilipsHealth.

For more information on Philips IntelliSpace Portal 6 with TAVI application, visit http://www.usa.philips.com/healthcare.

¹ The PARTNER Trial Investigators. Transcatheter aortic-valve implantation for aortic stenosis in patients who cannot undergo surgery. N Engl J Med. 2013 Oct 21; 363 (17): 1597-607. Doi: 10.1056/NEJMoal008232. Epub 2010 Sep 22.

About Royal Philips:
Royal Philips (NYSE: PHG, AEX: PHIA) is a diversified health and well-being company, focused on improving people's lives through meaningful innovation in the areas of Healthcare, Consumer Lifestyle and Lighting. Headquartered in the Netherlands, Philips posted 2013 sales of EUR 23.3 billion and employs approximately 112,000 employees with sales and services in more than 100 countries. The company is a leader in cardiac care, acute care and home healthcare, energy efficient lighting solutions and new lighting applications, as well as male shaving and grooming and oral healthcare. News from Philips is located at www.philips.com/newscenter.

Logo - http://photos.prnewswire.com/prnh/20140122/NE50581LOGO

SOURCE Royal Philips